Inscrivez-vous gratuitement à la newsletter :
Utilisez la recherche :
Stratégie Sectorielle : Soins de santé
Dividendes et valorisation des principales sociétés cotées américaines des soins de santé.
- Vous n’êtes pas identifié.
-
Stratégie Sectorielle
Soins de santé
Méga capitalisations boursières4 (Cap. ≥ 200 Md€)
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
 | Johnson & Johnson | 308,3 | 2,9% | 14,3 | 0,8 | 130,3 | -7% | 14% | Drug Manufacturers - Major |
| UnitedHealth Group | 217,3 | 1,7% | 15,4 | 0,7 | 256,7 | -19% | 12% | Health Care Plans |
| Pfizer | 211,9 | 3,3% | 14,0 | 0,4 | 42,8 | -13% | 9% | Drug Manufacturers - Major |
Grosses capitalisations boursières4 (200 Md€ > Cap. ≥ 10 Md€)
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
| Merck | 186,7 | 2,7% | 15,3 | 0,3 | 81,4 | -23% | 7% | Drug Manufacturers - Major |
| Abbott Laboratories | 137,5 | 1,5% | 24,2 | 0,9 | 87,5 | -28% | 1% | Medical Devices |
| Medtronic | 120,5 | 2,1% | 17,0 | 0,5 | 100,8 | -19% | 2% | Medical Devices |
| Thermo Fisher Scientific | 103,3 | 0,3% | 21,2 | 1,2 | 289,8 | -28% | 5% | Diagnostics & Research |
| Amgen | 97,0 | 3,2% | 12,1 | 1,0 | 178,4 | -7% | 18% | Drug Manufacturers - Major |
| Eli Lilly | 92,4 | 2,4% | 16,2 | 0,3 | 106,8 | -17% | 24% | Drug Manufacturers - Major |
| Danaher | 90,3 | 0,5% | 24,8 | 0,8 | 141,6 | -33% | 3% | Diagnostics & Research |
| AbbVie | 90,3 | 6,3% | 7,3 | 0,8 | 68,5 | -5% | 46% | Drug Manufacturers - Major |
| Gilead Sciences | 73,7 | 3,8% | 9,4 | 1,1 | 65,0 | -7% | 22% | Drug Manufacturers - Major |
| Stryker | 69,3 | 1,0% | 23,3 | 1,0 | 208,0 | -30% | 1% | Medical Devices |
| Anthem | 69,2 | 1,1% | 13,2 | 0,8 | 302,1 | -25% | 5% | Health Care Plans |
| Bristol-Myers Squibb | 63,2 | 3,7% | 9,7 | 0,7 | 43,3 | 0% | 47% | Drug Manufacturers - Major |
| Becton Dickinson | 60,3 | 1,2% | 19,2 | 1,2 | 250,8 | -17% | 6% | Medical Instruments & Supplies |
| Cigna | 58,7 | - | 9,3 | 1,0 | 173,7 | -18% | 30% | Health Care Plans |
| CVS Health | 58,1 | 3,6% | 7,8 | 1,1 | 55,9 | -8% | 47% | Health Care Plans |
| Celgene | 56,7 | - | 7,2 | 1,6 | 90,2 | -35% | 10% | Drug Manufacturers - Major |
| Intuitive Surgical | 54,4 | - | 39,1 | 1,3 | 528,8 | -19% | 11% | Medical Instruments & Supplies |
| Boston Scientific | 52,4 | - | 23,6 | 0,7 | 42,3 | -25% | 3% | Medical Devices |
| Zoetis | 48,7 | 0,6% | 29,5 | 0,7 | 114,1 | -31% | 2% | Drug Manufacturers - Specialty & Generic |
| Allergan | 47,7 | 1,8% | 9,5 | 2,0 | 163,2 | -30% | 21% | Drug Manufacturers - Specialty & Generic |
| HCA Healthcare | 42,5 | 1,1% | 12,3 | 1,3 | 139,5 | -23% | 6% | Medical Care |
| Biogen | 40,0 | - | 7,5 | 1,5 | 231,3 | -7% | 68% | Drug Manufacturers - Major |
| Vertex Pharmaceuticals | 39,7 | - | 28,8 | 1,2 | 174,1 | -13% | 12% | Biotechnology |
| Illumina | 38,4 | - | 39,9 | 1,3 | 293,2 | -8% | 30% | Diagnostics & Research |
| Baxter International | 37,8 | 1,1% | 22,3 | 1,1 | 83,1 | -27% | 1% | Medical Instruments & Supplies |
| Edwards Lifesciences | 36,0 | - | 33,2 | 1,0 | 194,3 | -31% | 2% | Medical Devices |
| Humana | 33,9 | 0,8% | 15,0 | 1,0 | 281,7 | -20% | 26% | Health Care Plans |
| Regeneron Pharmaceuticals | 29,1 | - | 12,3 | 1,0 | 298,1 | -4% | 48% | Biotechnology |
| IQVIA Holdings | 27,4 | - | 21,6 | 1,2 | 155,9 | -33% | 5% | Diagnostics & Research |
| Alexion Pharmaceuticals | 24,1 | - | 11,2 | 1,8 | 120,8 | -23% | 17% | Biotechnology |
| McKesson | 23,1 | 1,1% | 906,7 | 1,3 | 138,9 | -24% | 7% | Medical Distribution |
| Zimmer Biomet Holdings | 22,5 | 0,8% | 14,9 | 1,3 | 123,5 | -21% | 9% | Medical Devices |
| IDEXX Laboratories | 21,8 | - | 51,5 | 1,2 | 284,7 | -38% | 3% | Diagnostics & Research |
| Align Technology | 20,0 | - | 39,2 | 2,4 | 281,2 | -37% | 42% | Medical Devices |
| Centene | 19,4 | - | 10,7 | 0,8 | 52,7 | -14% | 41% | Health Care Plans |
| Agilent Technologies | 19,3 | 0,9% | 20,3 | 1,3 | 68,7 | -11% | 20% | Diagnostics & Research |
| Mettler-Toledo International | 18,0 | - | 31,9 | 1,4 | 813,9 | -38% | 7% | Diagnostics & Research |
| AmerisourceBergen | 16,0 | 1,8% | 11,6 | 1,2 | 85,5 | -19% | 11% | Medical Distribution |
| ResMed | 15,8 | 1,2% | 31,7 | 0,3 | 123,5 | -27% | 2% | Medical Instruments & Supplies |
| Incyte | 15,4 | - | 27,6 | 1,0 | 80,5 | -29% | 11% | Biotechnology |
| Laboratory of America Holdings | 15,2 | - | 14,3 | 1,0 | 173,2 | -31% | 9% | Diagnostics & Research |
| The Cooper | 14,6 | - | 25,0 | 0,9 | 331,5 | -31% | 4% | Medical Instruments & Supplies |
| Teleflex | 13,8 | 0,4% | 26,3 | 1,1 | 335,1 | -33% | 2% | Medical Instruments & Supplies |
| Waters | 13,2 | - | 20,9 | 1,1 | 213,7 | -21% | 19% | Diagnostics & Research |
| Exact Sciences | 13,2 | - | -99,9 | 2,4 | 114,9 | -58% | 6% | Diagnostics & Research |
| BioMarin Pharmaceutical | 13,0 | - | 271,9 | 1,2 | 81,6 | -3% | 31% | Biotechnology |
| WellCare Health Plans | 12,9 | - | 17,5 | 1,0 | 286,9 | -23% | 13% | Health Care Plans |
| DexCom | 12,4 | - | 127,2 | 1,0 | 152,6 | -39% | 3% | Diagnostics & Research |
| Cardinal Health | 11,9 | 4,3% | 877,0 | 1,7 | 45,0 | -7% | 30% | Medical Distribution |
| Quest Diagnostics | 11,9 | 2,1% | 14,6 | 0,9 | 99,3 | -20% | 16% | Diagnostics & Research |
| DENTSPLY SIRONA | 11,8 | 0,6% | 21,2 | 0,7 | 56,7 | -40% | 5% | Medical Instruments & Supplies |
| Hologic | 11,5 | - | 18,4 | 1,0 | 48,3 | -22% | 3% | Medical Instruments & Supplies |
 | Canopy Growth | 10,9 | - | -125,2 | 5,2 | 46,3 | -31% | 66% | Drug Manufacturers - Specialty & Generic |
| Seattle Genetics | 10,8 | - | -139,0 | 1,8 | 75,1 | -32% | 12% | Biotechnology |
| Varian Medical Systems | 10,8 | - | 24,8 | 0,9 | 132,8 | -24% | 7% | Medical Instruments & Supplies |
| Universal Health Services | 10,7 | 0,3% | 12,3 | 1,2 | 132,6 | -15% | 7% | Medical Care |
| Abiomed | 10,5 | - | 44,8 | 1,0 | 260,5 | -12% | 77% | Medical Devices |
Moyennes capitalisations boursières4 (10 Md€ > Cap. ≥ 2 Md€)
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | 9,9 | - | -50,4 | 1,8 | 149,3 | -36% | 11% | Biotechnology |
| PerkinElmer | 9,3 | 0,3% | 20,4 | 1,5 | 93,8 | -23% | 10% | Diagnostics & Research |
| Array BioPharma | 9,2 | - | -132,8 | 1,6 | 46,5 | -73% | 1% | Biotechnology |
| Henry Schein | 9,0 | - | 18,0 | 0,8 | 67,5 | -16% | 8% | Medical Distribution |
| Ionis Pharmaceuticals | 8,6 | - | 264,5 | 1,7 | 68,8 | -40% | 26% | Biotechnology |
| Mylan | 8,3 | - | 4,0 | 2,1 | 18,1 | -8% | 119% | Drug Manufacturers - Specialty & Generic |
| DaVita | 8,3 | - | 10,7 | 2,1 | 56,1 | -23% | 41% | Medical Care |
| West Pharmaceutical Services | 8,0 | 0,5% | 36,5 | 1,4 | 121,4 | -24% | 5% | Medical Instruments & Supplies |
| Bausch Health | 7,3 | - | 8,0 | 1,8 | 30,3 | -22% | 21% | Drug Manufacturers - Specialty & Generic |
| Alnylam Pharmaceuticals | 7,2 | - | -10,4 | 2,4 | 75,4 | -20% | 65% | Biotechnology |
| Jazz Pharmaceuticals | 6,9 | - | 7,9 | 1,0 | 136,6 | -17% | 33% | Biotechnology |
| bluebird bio | 6,8 | - | -11,6 | 2,8 | 138,1 | -37% | 30% | Biotechnology |
| Perrigo | 6,2 | 1,6% | 12,0 | 1,9 | 51,6 | -30% | 56% | Drug Manufacturers - Specialty & Generic |
| Charles River Laboratories International | 5,9 | - | 18,4 | 1,2 | 135,6 | -24% | 10% | Diagnostics & Research |
| PRA Health Sciences | 5,8 | - | 17,6 | 1,5 | 99,5 | -17% | 23% | Diagnostics & Research |
| Exelixis | 5,7 | - | 17,6 | 1,7 | 21,3 | -37% | 19% | Biotechnology |
| Nektar Therapeutics | 5,0 | - | -11,9 | 3,0 | 32,0 | -9% | 118% | Biotechnology |
| Syneos Health | 4,5 | - | 13,5 | 1,5 | 48,2 | -25% | 17% | Diagnostics & Research |
| Moderna | 4,1 | - | -7,8 | - | 14,1 | -8% | 111% | Biotechnology |
| FibroGen | 3,6 | - | 513,7 | 2,2 | 46,2 | -28% | 47% | Biotechnology |
| Mirati Therapeutics | 3,4 | - | -19,3 | 2,4 | 106,0 | -73% | 3% | Biotechnology |
| Spark Therapeutics | 3,3 | - | -23,8 | 1,4 | 96,9 | -64% | 18% | Biotechnology |
| Alkermes | 3,3 | - | -465,4 | 1,5 | 23,3 | -9% | 102% | Biotechnology |
| Allogene Therapeutics | 3,0 | - | -11,8 | - | 28,0 | -23% | 27% | Biotechnology |
| United Therapeutics | 2,9 | - | 9,4 | 0,9 | 75,3 | 0% | 73% | Biotechnology |
| Iovance Biotherapeutics | 2,8 | - | -18,2 | 2,2 | 25,5 | -71% | 4% | Biotechnology |
| CRISPR Therapeutics | 2,4 | - | -11,9 | 3,1 | 49,0 | -55% | 20% | Biotechnology |
| Invitae | 2,0 | - | -16,3 | 3,1 | 24,2 | -68% | 11% | Diagnostics & Research |
Petites capitalisations boursières4 (2 Md€ > Cap. ≥ 300 M€)
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
| Intercept Pharmaceuticals | 2,0 | - | -7,3 | 1,3 | 68,6 | -1% | 95% | Biotechnology |
| Acceleron Pharma | 2,0 | - | -26,6 | 0,8 | 42,3 | -13% | 41% | Biotechnology |
| Ligand Pharmaceuticals | 2,0 | - | 30,1 | 1,7 | 113,6 | -13% | 145% | Biotechnology |
| Myriad Genetics | 1,9 | - | 15,3 | 1,4 | 28,5 | -23% | 77% | Diagnostics & Research |
| Portola Pharmaceuticals | 1,6 | - | -9,2 | 2,6 | 26,6 | -44% | 58% | Biotechnology |
| AnaptysBio | 1,3 | - | -11,7 | 1,4 | 54,6 | -5% | 102% | Biotechnology |
| Fate Therapeutics | 1,2 | - | -16,2 | 2,2 | 21,4 | -60% | 7% | Biotechnology |
| Sangamo Therapeutics | 1,2 | - | -8,9 | 2,3 | 11,6 | -46% | 66% | Biotechnology |
| Intrexon | 1,1 | - | -6,1 | 2,0 | 7,5 | -47% | 168% | Biotechnology |
| Editas Medicine | 1,0 | - | -8,5 | 2,4 | 23,9 | -25% | 52% | Biotechnology |
| Epizyme | 1,0 | - | -7,1 | 2,1 | 12,7 | -60% | 30% | Biotechnology |
| NanoString Technologies | 1,0 | - | -16,5 | 1,4 | 31,8 | -65% | 4% | Biotechnology |
| Dicerna Pharmaceuticals | 0,9 | - | -10,9 | 2,0 | 15,1 | -38% | 19% | Biotechnology |
| Homology Medicines | 0,8 | - | -8,9 | - | 20,8 | -28% | 53% | Biotechnology |
| ZIOPHARM Oncology | 0,8 | - | -22,8 | 2,9 | 5,5 | -72% | 15% | Biotechnology |
| Intellia Therapeutics | 0,7 | - | -6,1 | 2,6 | 17,1 | -35% | 93% | Biotechnology |
| Kura Oncology | 0,6 | - | -9,4 | 2,3 | 19,1 | -46% | 15% | Biotechnology |
| MacroGenics | 0,6 | - | -3,7 | 1,4 | 14,7 | -33% | 120% | Biotechnology |
| TG Therapeutics | 0,6 | - | -5,8 | 2,1 | 7,7 | -57% | 67% | Biotechnology |
| CytomX Therapeutics | 0,5 | - | -4,1 | 0,6 | 11,6 | -23% | 134% | Biotechnology |
| Dermira | 0,4 | - | -1,8 | 1,8 | 8,4 | -28% | 85% | Biotechnology |
1 Ou contre-valeur en € d’après la parité en vigueur 2 Prévision si disponible 3 Ecart par rapport au +bas/haut à 52 semaines
4 Les données peuvent comporter des inexactitudes : ne prenez pas de décisions d’investissement sur leur seule base.
Déposez vos remarques et suggestions sur les forums : Screeners de l’IH.